Educational article

Aminoglycosides

Aminoglycosides bind the bacterial ribosome and disturb protein synthesis. Energy-dependent uptake contributes to their poor activity against anaerobes. Gentamicin, amikacin and tobramycin differ in spectrum and…

Overview

Aminoglycosides bind the bacterial ribosome and disturb protein synthesis. Energy-dependent uptake contributes to their poor activity against anaerobes. Gentamicin, amikacin and tobramycin differ in spectrum and vulnerability to modifying enzymes.

Biology and practical meaning

Resistance may involve modifying enzymes, rRNA methylation or impaired uptake. High-level resistance in enterococci has a specific role in assessing possible synergy. A synergy screen and a conventional susceptibility category answer different questions.

Spectrum, exposure and AST

Spectrum describes the range of organisms an agent can act against; activity against a particular isolate is assessed separately. Access to the target, target changes, enzymes and efflux can alter activity. Agents in the same class are not completely interchangeable.

Pharmacokinetics describes distribution and elimination; pharmacodynamics links exposure to effect. Blood concentrations and exposure at the infection site can differ. A lower MIC number for a different antibiotic therefore does not establish superior clinical activity.

S, I and R are interpreted using a current standard for the organism–agent pair. Under EUCAST, I means susceptible with increased exposure. It does not mean resistant and does not independently specify a treatment regimen. Decisions also depend on the site, patient, contraindications, interactions and current guidance. This article explains mechanisms and terminology. The 2025 AWaRe classification concerns use policy, while the 2022 AWaRe book has subsequent updates; neither replaces an individual AST result.

Sources

Read next

Educational material from AMR Atlas. Does not replace clinical guidance or laboratory procedures.

Open interactive reader